On a full-year basis from the audited filings, revenue rose 27.3% from KRW 16.1 billion in 2024 to KRW 20.5 billion in 2025, and the company described this as its highest annual revenue on record.
Over the same period the operating loss widened from KRW 9.17 billion to KRW 11.1 billion, moving the operating margin from -56.9% to -53.8%. Higher research and development and selling and administrative expenses were cited as reasons losses grew despite higher sales.
The net loss attributable to controlling shareholders narrowed from KRW 32.7 billion to KRW 11.7 billion, and the net loss including non-controlling interests shows the same figures. The filings show losses in both 2024 and 2025.
The debt ratio fell from 470.0% at the end of 2024 to 88.6% at the end of 2025, and total equity of KRW 21.1 billion at the end of 2025 is entirely attributable to controlling shareholders. Operating cash flow worsened from KRW -9.62 billion in 2024 to KRW -15.1 billion in 2025.
Quarterly revenue peaked at KRW 10.4 billion in the fourth quarter of 2025, fell to KRW 3.35 billion in the first quarter of 2026, recovered to KRW 6.28 billion in the second quarter, and dropped again to KRW 3.06 billion in the third quarter.
One brokerage noted that fourth-quarter results can look relatively strong because clinic adoption decisions tend to concentrate toward year-end. Third-quarter 2026 operating loss of KRW 5.33 billion was larger than the KRW 3.72 billion loss in the third quarter of 2025, and revenue fell 11.1% year on year.
Coverage in August 2026 cited a second-quarter consolidated gross margin of 77.8%, with SMA finished-product shipments up 98.9% year on year. A brokerage attributed continued losses partly to a selling and administrative expense ratio of 147.8% in the first half of 2025.
The net loss attributable to controlling shareholders over the most recent four quarters totals KRW 15.5 billion.